Olivier Valdenaire
Vorstandsvorsitzender bei Axovan AG
Profil
Olivier Valdenaire has founded Axovan AG in 2000, where he holds the title of Chief Executive Officer.
Currently, he is the Chief Executive Officer at Mestex AG and a Director at OncoEthix SA. In the past, he was the Chief Executive Officer at Lumavita AG and a Venture Partner at Endeavour Vision SA from 2010 to 2013.
Dr. Valdenaire has a doctorate degree from Université de Paris XI Paris Sud and an undergraduate degree from École Nationale Supérieure des Mines de Paris.
Aktive Positionen von Olivier Valdenaire
Unternehmen | Position | Beginn |
---|---|---|
Axovan AG
Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Vorstandsvorsitzender | 01.04.2000 |
OncoEthix SA
OncoEthix SA Pharmaceuticals: MajorHealth Technology OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland. | Direktor/Vorstandsmitglied | - |
Mestex AG
Mestex AG Pharmaceuticals: MajorHealth Technology Part of Grünenthal Pharma GmbH & Co. KG, Mestex AG is a Swiss pharmaceutical manufacturing company. The company is based in Basel, Switzerland. The CEO of the company is Olivier Valdenaire. Mestex was acquired by Grünenthal GmbH on April 12, 2021. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Olivier Valdenaire
Unternehmen | Position | Ende |
---|---|---|
Lumavita AG
Lumavita AG Medical/Nursing ServicesHealth Services Lumavita AG is a specialty biopharmaceutical company dedicated to bring to market innovative anti-infectives for women's health. Based in Basel, Switzerland, Lumavita was recently financed by a syndicate, lead by Atlas Venture, with CHF18 million (EUR11 million). The company has one product under regulatory review in Switzerland and two further projects in clinical development. | Vorstandsvorsitzender | 07.01.2014 |
Endeavour Vision SA
Endeavour Vision SA Investment ManagersFinance Endeavour Vision SA (EV) is an independent venture capital firm headquartered in Geneva. EV traces their origins back to 1989 through the convergence of the Vision Capital European team and the Swiss VC firm, Endeavour. EV was co-founded in 2000 by Sven Lingjaerde and Damien Tappy. The firm specializes in providing funding for entrepreneurs in life sciences, biotech, medtech, cleantech and information technology. EV operates in close cooperation with Genevest, an independent investment vehicle which has reached the divestment stage. Their investors in the funds they advise are industrial corporations, family offices, global institutional investors and business leaders in the technology and investment industry. | Private-Equity-Analyst | 01.06.2007 |
Ausbildung von Olivier Valdenaire
École Nationale Supérieure des Mines de Paris | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Axovan AG
Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Commercial Services |
Endeavour Vision SA
Endeavour Vision SA Investment ManagersFinance Endeavour Vision SA (EV) is an independent venture capital firm headquartered in Geneva. EV traces their origins back to 1989 through the convergence of the Vision Capital European team and the Swiss VC firm, Endeavour. EV was co-founded in 2000 by Sven Lingjaerde and Damien Tappy. The firm specializes in providing funding for entrepreneurs in life sciences, biotech, medtech, cleantech and information technology. EV operates in close cooperation with Genevest, an independent investment vehicle which has reached the divestment stage. Their investors in the funds they advise are industrial corporations, family offices, global institutional investors and business leaders in the technology and investment industry. | Finance |
Lumavita AG
Lumavita AG Medical/Nursing ServicesHealth Services Lumavita AG is a specialty biopharmaceutical company dedicated to bring to market innovative anti-infectives for women's health. Based in Basel, Switzerland, Lumavita was recently financed by a syndicate, lead by Atlas Venture, with CHF18 million (EUR11 million). The company has one product under regulatory review in Switzerland and two further projects in clinical development. | Health Services |
OncoEthix SA
OncoEthix SA Pharmaceuticals: MajorHealth Technology OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland. | Health Technology |
Université de Paris XI Paris Sud | Consumer Services |
Mestex AG
Mestex AG Pharmaceuticals: MajorHealth Technology Part of Grünenthal Pharma GmbH & Co. KG, Mestex AG is a Swiss pharmaceutical manufacturing company. The company is based in Basel, Switzerland. The CEO of the company is Olivier Valdenaire. Mestex was acquired by Grünenthal GmbH on April 12, 2021. | Health Technology |